Magnus Medical raised $25 million in Series A financing co-led by JAZZ Venture Partners and Red Tree Venture Capital.
The company also announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its individualized, rapid-acting, non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments. Read more.
Magnus Medical Raises $25M in Series A
